Can Treprostinil Change IPF Care?

Inhaled treprostinil resulted in a smaller decline in lung function and fewer clinical‐worsening events than placebo over 52 weeks.

By
Kathryn Wighton
August 12, 2026
4 min

MDSpire News

Overview

The phase 3 TETON-1 trial evaluated inhaled treprostinil in 598 patients with idiopathic pulmonary fibrosis (IPF), finding a smaller decline in forced vital capacity (FVC) and fewer clinical worsening events compared to placebo over 52 weeks.

Background

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by a decline in lung function and poor prognosis. Current treatment options primarily include antifibrotic therapies like nintedanib and pirfenidone.

Data Highlights

Parameter	Treprostinil	Placebo
Median Change in FVC at Week 52	-43 mL	-196 mL
Clinical Worsening Events	32%	45%
Adverse Events Leading to Discontinuation	21%	15%

Key Findings

Treatment with inhaled treprostinil resulted in a smaller decline in FVC compared to placebo (−43 mL vs. −196 mL).
Clinical worsening occurred in 32% of patients receiving treprostinil versus 45% in the placebo group.
A relative decline of at least 10% in predicted FVC was the most common clinical worsening event.
Cough was reported in 55% of patients receiving treprostinil compared to 33% receiving placebo.
Serious adverse events occurred in 18% of treprostinil patients and 24% of placebo patients.
Overall treatment discontinuation rates were 41% for treprostinil and 33% for placebo.